|
Mutation Information
|
Mutation Site
|
L74I |
|
Mutation Type
|
Amino acid level |
|
Gene/Protein/Region Type
|
IN |
|
Relevant Drug
|
dolutegravir (DTG) |
|
Country
|
Russia |
Literature Information
|
PubMed PMID
|
33136751
|
|
Disease
|
HIV infection/AIDS
|
|
Published Year
|
2020 |
|
Journal
|
Journal of acquired immune deficiency syndromes (1999) |
|
Title
|
Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials. |
|
Author
|
Rizzardini G,Overton ET,Orkin C,Swindells S,Arasteh K,Górgolas Hernández-Mora M,Pokrovsky V,Girard PM,Oka S,Andrade-Villanueva JF,Richmond GJ,Baumgarten A,Masiá M,Latiff G,Griffith S,Harrington CM,Hudson KJ,St Clair M,Talarico CL,Patel P,Cutrell A,Van Eygen V,D'Amico R,Mrus JM,Wu S,Ford SL,Chow K,Roberts J,Wills A,Walters N,Vanveggel S,Van Solingen-Ristea R,Crauwels H,Smith KY,Spreen WR,Margolis DA |
|
Evidence
|
Of the 6 participants, NNRTI (n = 2) resistance mutations and the INSTI L74I polymorphism (n = 5) were present at baseline;all retained full susceptibility to dolutegravir at suspected virologic failure timepoint (below clinical cut-off of 4.0-fold change).
|
|
|
HIV Mutation Detail Information